Use of multikinase inhibitors/lenvatinib in patients with high cardiovascular risk/vasculopathy and radioiodine refractory‐differentiated thyroid cancer

Antiangiogenic tyrosine kinase inhibitors are the treatment of choice in radioiodine refractory‐differentiated thyroid cancer (RR‐DTC). Nevertheless, these therapies present class toxicities that may impact their feasibility and patient's quality of life. Their mechanism of action explains the...

Descripción completa

Detalles Bibliográficos
Autor principal: Jimenez‐Fonseca, Paula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537056/
https://www.ncbi.nlm.nih.gov/pubmed/36202605
http://dx.doi.org/10.1002/cam4.5127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537056/
https://www.ncbi.nlm.nih.gov/pubmed/36202605
http://dx.doi.org/10.1002/cam4.5127

Ejemplares similares